Scalper1 News
We’re in the middle of another big week for earnings, with a slew of medical-related companies among those reporting. Regeneron (REGN) hit a new high in the stock market today after issuing better-than-expected Q2 earnings. The biotech also raised its growth forecast for its blockbuster Eylea drug. Shares gapped up 6% in big volume, hitting a fresh high and clearing the 600 price level for the first time intraday. Regeneron is now extended from a Scalper1 News
Scalper1 News